Combining the new biologic agents with our current psoriasis armamentarium (Q35190107)

7 August 2017

1 reference

title

Combining the new biologic agents with our current psoriasis armamentarium (English)

1 reference

7 August 2017

Mark Lebwohl

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

Journal of the American Academy of Dermatology

7 August 2017

published in

1 reference

7 August 2017

1 reference

7 August 2017

issue

2 Suppl

1 reference

7 August 2017

page(s)

S118-24

1 reference

A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Compatibility of calcipotriene with other topical medications

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Calcipotriol improves the response of psoriasis to PUVA.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Interactions between calcipotriene and ultraviolet light

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Acitretin in combination with UVB or PUVA.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Combined Methotrexate and Hydroxyurea Therapy for Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Combination therapy for psoriasis with methotrexate and etretinate

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

An approach to the treatment of moderate to severe psoriasis with rotational therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Cutaneous manifestations of immunosuppression in organ transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Immune function in patients with rheumatoid arthritis treated with etanercept

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Experience with etanercept in an academic medical center: are infection rates increased?

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Invasive Pulmonary Aspergillosis Associated with Infliximab Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Possible activation of an intramyocardial inflammatory process ( Staphylococcus aureus)after treatment with infliximab in a boy with Crohn disease

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

The relationship between infliximab treatment and lymphoma in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2901144-7

7 January 2021

10.1016/S0190-9622(03)01144-7

Identifiers

DOI

1 reference

7 August 2017

1 reference